InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
58,222.60
(
-0.13%
)
Post# of 252498
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: DewDiligence post# 124058

Thursday, 07/28/2011 11:22:32 PM

Thursday, July 28, 2011 11:22:32 PM

Post# of 252498
SNY said Thursday it does not expect to meet a production milestone that would have triggered a $1 payout to holders of the contingent value right (CVR) of recently acquired Genzyme Corp.

The $1 milestone is tied to production levels of two Genzyme drugs: Fabrazyme agalsidase beta for Fabry's disease and Cerezyme imiglucerase for Gaucher's disease. Sanofi does not expect to meet end-of-year supply goals for Fabrazyme. Sanofi did say it is supplying Cerezyme globally at normal dosing levels.

http://www.bizjournals.com/boston/news/2011/07/28/genzyme-misses-milestone-drug.html?ana=yfcpc
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up